Methoxyamine hydrochloride - TRACON

Drug Profile

Methoxyamine hydrochloride - TRACON

Alternative Names: Methoxyamine - TRACON; TRC 102

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TRACON Pharmaceuticals
  • Developer Case Western Reserve University; National Cancer Institute (USA); TRACON Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Mesothelioma
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies; Lymphoma; Non-small cell lung cancer

Most Recent Events

  • 13 Nov 2017 Adverse events data from a phase I trial in Haematological malignancies released by TRACON Pharmaceuticals
  • 15 Jun 2017 Methoxyamine hydrochloride is still in phase I trial for Lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) and in phase-I development in Solid-tumours (Combination therapy, Late-stage disease) in USA (IV, Infusion) (NCT01851369; NCT00892385)
  • 02 Jun 2017 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top